If you inject compounded tirzepatide, here's a small job for today: read the pharmacy name on your vial. A Houston pharmacy has recalled some of its vials, and the FDA's inspection notes show why. Welcome to GLP-1 Daily. It's Wednesday, October 21. After that recall: Belgium's drug regulator on who these medicines are actually for, and new CagriSema numbers in women ahead of an FDA decision.
Cole Mercer, reporting for Medical Daily:
Inspectors also wrote that on August 3 the pharmacy recovered microbial growth in the ISO 5 hood after filling a lot of tirzepatide-niacinamide. No investigation followed because the firm's action level was not appropriate, according to the FDA, and that lot was released and partially distributed.
That hood is the cleanest workspace in the building. The pharmacy is Houston RX, and inspectors spent six days there in late August. Their Form 483 lists fourteen observations. An operator stoppering vials with skin exposed on her forehead. Cleanroom air pressure running the wrong way for about six weeks, with lots made in that stretch released anyway. Then the ingredients. Certificates for the tirzepatide and semaglutide were marked for research and development only, and the niacinamide in its GLP-1 formulas met a dietary supplement standard, not a pharmaceutical one. On Monday we covered FDA findings at two Chinese ingredient makers. This is a different link in the chain: the pharmacy that fills the vial. Starting September 25, Houston RX pulled sixty-four vials of tirzepatide with niacinamide over a lack of assurance of sterility. It's Class II, the tier where serious harm is considered unlikely, and FDA data lists distribution as nationwide. Becker's also reports Apothecary Pharma in North Carolina is recalling twenty-two vials of compounded tirzepatide for the same reason. Limits: a Form 483 isn't a final FDA determination, Medical Daily found no public response from Houston RX, and no illnesses tied to these vials have been publicly reported. One pharmacy's record isn't a verdict on every compounder. Agreed. But a telehealth company's own survey, which nobody has independently verified, puts compounded tirzepatide at a median two hundred twenty-two dollars a month. People pick that because the brand is out of reach, and nobody can see sterility by holding a vial up to the light. If you're on compounded tirzepatide, ask your prescriber or pharmacy who filled it, and whether a replacement from another source makes sense. Don't stop on your own. Spreading redness, swelling or pus at the injection site deserves a call. Fever, chills or a racing heart after a shot needs urgent care.
Belgium's medicines agency, the FAMHP, in a public notice dated Monday:
In practice: for weight loss in people who are neither obese nor demonstrably overweight – and where this is not associated with health problems – the risks associated with treatment may outweigh the potential benefits.
The agency says it was alerted to cases of misuse and off-label use, mostly for weight loss, so it restated the rules. In Belgium, only Saxenda, Wegovy and Mounjaro are indicated for weight management: a BMI of thirty or more, or twenty-seven or more with a weight-related condition. Ozempic there is for type 2 diabetes only. It also names a habit worth knowing: golden dosing, meaning squeezing leftover medicine out of a pen for an extra dose. The agency says that can cause dosing errors, low blood sugar and injection-site infection. And a higher dose, it says, won't speed up weight loss. Then comes a line flagged in capital letters. Triple agonists like retatrutide, it says, are already sold online and on the black market while they're still under investigation. On October 14 we covered two U.S. death reports naming bootleg retatrutide. Now a European regulator is flagging the same market. The rules are Belgian, but the advice travels. If you're tempted to push your dose, ask your prescriber first.
From Novo Nordisk's own press release, on posters presented at The Menopause Society's annual meeting in San Diego:
CagriSema was associated with clinically meaningful weight loss across all menopause stages, with an average weight loss at week 68 of 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women.
CagriSema pairs semaglutide with cagrilintide, a long-acting amylin analog. These are two post hoc analyses of REDEFINE 1, Novo's sixty-eight-week phase 3 trial. Across all 2,309 women in it, Novo reports twenty-five percent average weight loss on CagriSema, three percent on placebo, and nineteen percent on semaglutide alone. Caveats, mostly from the release itself. This is company-reported poster data, not a peer-reviewed paper. The figures assume everyone stayed on treatment. Menopause status was assigned after the fact from age, history and symptoms, not hormone testing. And Novo itself calls post hoc analyses hypothesis generating. Side effects in the full trial were mostly gastrointestinal, with nausea in fifty-five percent on CagriSema versus about thirteen percent on placebo. And if it's approved, my first question is who covers it, when employers are already dropping the older drugs. Why it matters now: Novo filed with the FDA in December 2025 and expects a decision this quarter. CagriSema is not approved in the U.S. If you're wondering whether it could fit you, that's a prescriber conversation once there's a label to read.
One favor before we go. If GLP-1 Daily helps you read the fine print, leave us a rating or a couple of lines of review in your podcast app. That's how other patients stumble onto the show.
The Medical Daily report, the Belgian notice and Novo's release are all in the show notes. GLP-1 Daily returns tomorrow, Thursday. This has been a Lantern Podcast.